LGT Capital Partners LTD. Raises Stock Holdings in AdaptHealth Corp. (NASDAQ:AHCO)

LGT Capital Partners LTD. lifted its position in AdaptHealth Corp. (NASDAQ:AHCO) by 79.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,000,000 shares of the company’s stock after purchasing an additional 442,500 shares during the quarter. LGT Capital Partners LTD.’s holdings in AdaptHealth were worth $7,290,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Commonwealth Equity Services LLC grew its position in AdaptHealth by 1.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 28,364 shares of the company’s stock worth $532,000 after purchasing an additional 491 shares during the period. The Manufacturers Life Insurance Company increased its holdings in AdaptHealth by 2.9% in the second quarter. The Manufacturers Life Insurance Company now owns 30,979 shares of the company’s stock valued at $377,000 after buying an additional 887 shares in the last quarter. First Republic Investment Management Inc. raised its position in shares of AdaptHealth by 3.8% in the second quarter. First Republic Investment Management Inc. now owns 24,990 shares of the company’s stock worth $451,000 after acquiring an additional 924 shares during the period. ProShare Advisors LLC raised its holdings in AdaptHealth by 9.2% in the 2nd quarter. ProShare Advisors LLC now owns 11,574 shares of the company’s stock worth $141,000 after purchasing an additional 978 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of AdaptHealth by 2.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 37,652 shares of the company’s stock worth $469,000 after buying an additional 984 shares during the period. 82.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AHCO has been the subject of a number of research reports. UBS Group boosted their target price on shares of AdaptHealth from $9.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $13.00 price target on shares of AdaptHealth in a research note on Monday, March 4th. Truist Financial raised their price objective on AdaptHealth from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Finally, Jefferies Financial Group cut shares of AdaptHealth from a “buy” rating to a “hold” rating and reduced their target price for the company from $14.50 to $8.00 in a research report on Monday, January 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $12.10.

Insiders Place Their Bets

In related news, major shareholder James E. Flynn sold 182,607 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the completion of the transaction, the insider now directly owns 11,643,769 shares of the company’s stock, valued at approximately $128,314,334.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, major shareholder James E. Flynn sold 182,607 shares of AdaptHealth stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the transaction, the insider now owns 11,643,769 shares in the company, valued at $128,314,334.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder James E. Flynn sold 52,487 shares of AdaptHealth stock in a transaction on Friday, March 8th. The stock was sold at an average price of $10.93, for a total transaction of $573,682.91. Following the sale, the insider now directly owns 11,826,376 shares of the company’s stock, valued at $129,262,289.68. The disclosure for this sale can be found here. 13.60% of the stock is owned by company insiders.

AdaptHealth Stock Performance

NASDAQ:AHCO opened at $11.51 on Friday. AdaptHealth Corp. has a fifty-two week low of $6.37 and a fifty-two week high of $15.37. The company has a 50 day moving average price of $8.84 and a 200 day moving average price of $8.28. The stock has a market capitalization of $1.53 billion, a P/E ratio of -2.17, a PEG ratio of 0.74 and a beta of 1.01. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.00 and a current ratio of 1.21.

AdaptHealth (NASDAQ:AHCO) last announced its earnings results on Tuesday, February 27th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.44. The company had revenue of $858.23 million during the quarter, compared to analysts’ expectations of $825.94 million. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. Equities research analysts forecast that AdaptHealth Corp. will post 0.88 EPS for the current year.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.